PT955314E - Compostos peptidicos analogos do glucagon-like-peptido-1(7-37) processo para a sua preparacao e as composicoes farmaceuticas que os contem - Google Patents

Compostos peptidicos analogos do glucagon-like-peptido-1(7-37) processo para a sua preparacao e as composicoes farmaceuticas que os contem

Info

Publication number
PT955314E
PT955314E PT99400613T PT99400613T PT955314E PT 955314 E PT955314 E PT 955314E PT 99400613 T PT99400613 T PT 99400613T PT 99400613 T PT99400613 T PT 99400613T PT 955314 E PT955314 E PT 955314E
Authority
PT
Portugal
Prior art keywords
peptido
glucagon
analogue
preparing
pharmaceutical compositions
Prior art date
Application number
PT99400613T
Other languages
English (en)
Inventor
Gerard Grassy
Bruno Pfeiffer
Pierre Renard
Bernard Calas
Alain Chavanieu
Cyril Sarrauste De Menthiere
Dominique Manechez
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PT955314E publication Critical patent/PT955314E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT99400613T 1998-04-10 1999-03-12 Compostos peptidicos analogos do glucagon-like-peptido-1(7-37) processo para a sua preparacao e as composicoes farmaceuticas que os contem PT955314E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9804559A FR2777283B1 (fr) 1998-04-10 1998-04-10 Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PT955314E true PT955314E (pt) 2004-03-31

Family

ID=9525150

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99400613T PT955314E (pt) 1998-04-10 1999-03-12 Compostos peptidicos analogos do glucagon-like-peptido-1(7-37) processo para a sua preparacao e as composicoes farmaceuticas que os contem

Country Status (18)

Country Link
US (1) US6620910B1 (pt)
EP (1) EP0955314B1 (pt)
JP (1) JP3787242B2 (pt)
CN (1) CN1305897C (pt)
AT (1) ATE255596T1 (pt)
AU (1) AU761652B2 (pt)
BR (1) BR9902014A (pt)
CA (1) CA2263059A1 (pt)
DE (1) DE69913242T2 (pt)
DK (1) DK0955314T3 (pt)
ES (1) ES2212485T3 (pt)
FR (1) FR2777283B1 (pt)
HU (1) HUP9900604A3 (pt)
NO (1) NO323137B1 (pt)
NZ (1) NZ334379A (pt)
PL (1) PL331960A1 (pt)
PT (1) PT955314E (pt)
ZA (1) ZA992035B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002022151A2 (en) * 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004074315A2 (en) * 2003-02-19 2004-09-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Analogues of glp-1
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CA2550695A1 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
AU2006290205B2 (en) 2005-09-14 2012-12-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0522295D0 (en) * 2005-11-01 2005-12-07 Activotec Spp Ltd Peptides and uses thereof
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CN1982336B (zh) * 2006-03-03 2011-01-12 华东师范大学 一种人胰高血糖素样肽-1衍生物及其制备和应用
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN101463081B (zh) * 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
WO2010120476A2 (en) * 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
AU2011282745A1 (en) * 2010-07-28 2013-03-14 Amylin Pharmaceuticals, Llc GLP-1 receptor agonist compounds having stabilized regions
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
EP2820038B1 (en) * 2012-03-01 2020-06-17 Novo Nordisk A/S Glp-1 prodrugs
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
CN110070918B (zh) * 2019-04-02 2022-12-27 重庆邮电大学 基于分子间相互作用的粗粒化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
CA2137206A1 (en) * 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs

Also Published As

Publication number Publication date
ES2212485T3 (es) 2004-07-16
BR9902014A (pt) 2000-05-02
NO991199L (no) 1999-10-11
ZA992035B (en) 1999-09-27
JPH11310597A (ja) 1999-11-09
PL331960A1 (en) 1999-10-11
FR2777283A1 (fr) 1999-10-15
HK1022320A1 (en) 2000-08-04
AU761652B2 (en) 2003-06-05
EP0955314A2 (fr) 1999-11-10
ATE255596T1 (de) 2003-12-15
NO991199D0 (no) 1999-03-11
EP0955314A3 (fr) 2000-03-29
DE69913242D1 (de) 2004-01-15
CA2263059A1 (fr) 1999-10-10
DE69913242T2 (de) 2004-09-09
FR2777283B1 (fr) 2000-11-24
HUP9900604A2 (hu) 1999-09-28
CN1305897C (zh) 2007-03-21
JP3787242B2 (ja) 2006-06-21
NO323137B1 (no) 2007-01-08
US6620910B1 (en) 2003-09-16
CN1232038A (zh) 1999-10-20
AU2368899A (en) 1999-10-21
DK0955314T3 (da) 2004-04-13
NZ334379A (en) 1999-10-28
EP0955314B1 (fr) 2003-12-03
HU9900604D0 (en) 1999-05-28
HUP9900604A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
DK0955314T3 (da) Peptidanaloge af glucagon-lignende-peptid-1 (7-37), fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger
DE69831868D1 (en) Antithrombosemittel
AU2055500A (en) Aromatic amides
IL143545A (en) Thrombin inhibitors and pharmaceutical compositions containing them
AU2001280438A1 (en) Substituted heterocyclic amides
MY140057A (en) Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
MXPA02004603A (es) Sales estables de nuevos derivados de 3, 3-difenilpropilaminas.
ATE326453T1 (de) Antithrombotische amide
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
MY109846A (en) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
BG103656A (en) Fluoroether compositions and methods for their decomposition inhibition in the presence of lewis acid
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
PL349449A1 (en) Sulfonamide hydroxamates
PT1233953E (pt) Novos derivados de benzotiadiazinas processo para a sua preparacao e as composicoes farmaceuticas que os contem
DE60114640D1 (en) Antithrombosemittel
PL345802A1 (en) Process for the synthesis of (1h
NZ326283A (en) Diphenyl stilbenes as prodrugs to cox-2 inhibitors
PT83667B (pt) Processo para a preparacao de acidos e esteres {{{(3-piridinil)metileno}amino}oxi}-alcanoicos e de composicoes farmaceuticas que os contenham
Abebe et al. Novel post-translational oligomerization of peptidyl dehydrodopa model compound, 1, 2-dehydro-N-acetyldopa methyl ester
KR970705576A (ko) 페닐 펩티드, 이를 제조하는 방법, 및 이 펩티드를 함유하는 약제학적 조성물(phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides)
ES8703475A1 (es) Un procedimiento para la preparacion de derivados de 5-cetomilbemicina.
RU94045946A (ru) Фторированные производные 4-аминоандростадиенона, способ их получения, фармацевтическая композиция
DE69824410D1 (en) Antithrombosemittel